These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37723998)

  • 1. TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm).
    Xiang Z; Li G; Mu L; Wang H; Zhou C; Yan H; Huang M
    Technol Cancer Res Treat; 2023; 22():15330338231200320. PubMed ID: 37723998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.
    Ding Z; Fang G; Tang Y; Zeng Y
    Sci Rep; 2024 Jun; 14(1):14334. PubMed ID: 38906915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
    Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma.
    Wu J; Zeng J; Wang H; Huo Z; Hou X; He D
    Front Oncol; 2023; 13():1244341. PubMed ID: 37916160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
    Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study.
    Chen S; Shuangyan T; Shi F; Cai H; Wu Z; Wang L; Ma P; Zhou Y; Mai Q; Wang F; Lai J; Chen X; Chen H; Guo W
    Front Immunol; 2024; 15():1430571. PubMed ID: 39131156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
    Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
    Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J
    Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study.
    Jiang X; Wang P; Su K; Li H; Chi H; Wang F; Liu Y; Xu K
    Ann Hepatol; 2024 Sep; 30(2):101578. PubMed ID: 39276984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
    Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
    Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
    Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
    Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
    Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
    Acad Radiol; 2024 Nov; 31(11):4456-4465. PubMed ID: 38760273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Zong Z; Tang R; Li M; Xiong X; Li D; Fan J; Ye W; Xue C
    Turk J Gastroenterol; 2024 Mar; 35(3):212-222. PubMed ID: 39128062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
    Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
    Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
    Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
    Ren Y; Liu Z; Makamure J; Kan X; Song S; Liu Y; Qian K; Zheng C; Liang B
    Technol Cancer Res Treat; 2022; 21():15330338221131385. PubMed ID: 36259117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.